Skip to main content

Table 2 Positive rate of HBs antibody after HB vaccination

From: Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study

Vaccine Administration routeTotal numberAge range, median (IQR)HBs antibodyPositive rate (%)SexTotal numberAge range, median (IQR)HBs antibodyPositive rate (%)
Median (IQR)(+)(−)(+)(–)
Bimmugen® subcutaneous51419-25, 20 (19–21)84.9 (34.5–217) mIU/mL4734192.0*Men20419–25, 20 (19–21)1832189.1
Women31019–22, 19 (19–19)2902093.5
Heptavax-II® subcutaneous37319–30, 20 (19–21)28.7 (5–216) mIU/mL24812566.3*Men18019–30, 20 (19–21)1027256.7
Women19319–22, 19 (19–19)146775.3
Heptavax-II® intramuscular24719–27, 20 (19–21)190, (41.6–534) mIU/mL2202789.1*Men9719–27, 20 (19–21)791881.4
Women15019–22, 19 (19–20)141994.0
  1. *There was a significant difference among the Bimmugen® subcutaneous, Heptavax-II® subcutaneous, and Heptavax-II® intramuscular groups (p < 0.05)
  2. †,‡There were significant differences among the Bimmugen® subcutaneous, Heptavax-II® subcutaneous, and Heptavax-II® intramuscular groups in both men and women (p < 0.05)